Multiple Myeloma
Specialty Channel

Featured Article
The FDA has approved melphalan flufenamide plus dexamethasone for the treatment of patients with relapsed/refractory multiple myeloma (MM).
True or False: Ixazomib, an oral proteasome inhibitor, is ideal for multiple myeloma treatment due to a history of low rates of polyneuropathy and patient tolerability.
At the virtual Great Debates & Updates in Hematologic Malignancies, Dr Mikhael presented emerging therapies in multiple myeloma (MM).
Available clinical data presented at the virtual 2020 ASH Annual meeting finds P-BCMA-101 CAR-T therapy, targeting BCMA, can produce significant efficacy with low toxicity in patients with relapsed/…
Data being presented at the virtual 62nd ASH Annual Meeting and Exposition show that triplet therapy is superior to doublet therapy for the treatment of lenalidomide-refractory MM.
True or false: Data suggest that teclistamab is a promising therapy for patients with BCMA-positive MM.
The 2 most common treatment regimens administered to patients with MM are an RvD-like regimen and the combination of daratumumab, lenalidomide, and __________.
Real-world study findings show that therapy with ixazomib plus lenalidomide and dexamethasone yields significant clinical benefits in patients with relapsed/refractory MM.
True or False: Findings suggest that a correlation may exist between low education levels and poor survival in patients with multiple myeloma in China.

News

The FDA has approved melphalan flufenamide plus dexamethasone for the treatment of patients with relapsed/refractory multiple myeloma (MM).
At the virtual Great Debates & Updates in Hematologic Malignancies, Dr Mikhael presented emerging therapies in multiple myeloma (MM).
Available clinical data presented at the virtual 2020 ASH Annual meeting finds P-BCMA-101 CAR-T therapy, targeting BCMA, can produce significant efficacy with low toxicity in patients with relapsed/…
Data being presented at the virtual 62nd ASH Annual Meeting and Exposition show that triplet therapy is superior to doublet therapy for the treatment of lenalidomide-refractory MM.

Interactive Features

True or False: Ixazomib, an oral proteasome inhibitor, is ideal for multiple myeloma treatment due to a history of low rates of polyneuropathy and patient tolerability.
True or false: Data suggest that teclistamab is a promising therapy for patients with BCMA-positive MM.
The 2 most common treatment regimens administered to patients with MM are an RvD-like regimen and the combination of daratumumab, lenalidomide, and __________.
True or False: Findings suggest that a correlation may exist between low education levels and poor survival in patients with multiple myeloma in China.
Stay in the know.
OncNet Newsletter